Answers in CME

CME in Minutes: Education in Oncology & Hematology

Science EN ↓ 140 episodes

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access...

Author

Answers in CME

Episodes

Mastering Evolving Standards in Resectable HNSCC: A Case-Based Discussion to Elevate Pre- and Postoperative Care 10.07.2026 18:10

Please visit answersincme.com/DDT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Robert Haddad, MD. In this activity, an expert in medical oncology discusses locally advanced head and neck squamous cell carcinoma (LA HNSCC). Upon completion of this activity, participants should be better able to: Discuss the clinical implica...

Early Intervention, Extended Benefit: Transforming Tolerability Into Treatment Success in Later-Line Metastatic Colorectal Cancer 09.07.2026 30:01

Please visit answersincme.com/860/103518989-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John Strickler, MD and Tanios Bekaii-Saab, MD. In this activity, experts in metastatic colorectal cancer (mCRC) discuss proactive toxicity management and dose optimization strategies to help patients remain on treatment and improv...

Strategic Sequencing: Mapping the Optimal Path for Later-Line Metastatic Colorectal Cancer Care 07.07.2026 27:59

Please visit answersincme.com/860/103518989-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John Strickler, MD; and Daniel Ahn, DO, MS. In this activity, experts in metastatic colorectal cancer (mCRC) discuss strategies for sequencing later-line therapies and planning treatment pathways to preserve future options. Upon c...

The Immunotherapy Casebook: Practical Approaches in Frontline Metastatic NSCLC Treatment 03.07.2026 1:01:18

Please visit answersincme.com/860/102724337-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Charu Aggarwal, MD, MPH, FASCO; and Benjamin Levy, MD, FASCO. In this activity, expert oncologists will engage in a case-based discussion examining how current guidelines and evidence inform the use of frontline immunotherapy-based...

From Evidence to Action: Expert Dialogues on the Evolving Role of Immunotherapy in Basal Cell Carcinoma 01.07.2026 18:18

Please visit answersincme.com/UZA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Anne Lynn S. Chang, MD and Zeynep Eroglu, MD. In this activity, experts in nonmelanoma skin cancer discuss clinical advances for the use of immunotherapy for the management of basal cell carcinoma (BCC). Upon completion of this activity, partici...

Cornerstones of Clinical Care: A Guide for Nurses and NPs on Oral SERDs in Breast Cancer 30.06.2026 16:47

Please visit answersincme.com/GXT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sarah Donahue, MPH, ANP, AOCNP. In this activity an expert in breast cancer discusses the efficacy and safety of oral SERDs in HR+, HER2- advanced breast cancer. Upon completion of this activity, participants should be better able to: Review the...

Redefining Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Are You Prepared? 25.06.2026 1:01:09

Please visit answersincme.com/860/102769007-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aiwu Ruth He, MD, PhD and Mehmet Akce, MD. In this activity, experts in hepatocellular carcinoma (HCC) discuss how the current and emerging clinical evidence for immune checkpoint inhibitor (ICI)–based regimens can elevate personal...

The Promise of Oral Therapy for HER2-Mutated NSCLC: Unlocking New Treatment Opportunities With a Familiar Target 05.06.2026 1:13:30

Please visit answersincme.com/860/IME_2025_00012595-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John V. Heymach, MD, PhD; and Mark Awad, MD, PhD. In this activity, experts in oncology discuss the role of dual and HER2-selective oral tyrosine kinase inhibitors in patients with HER2-mutated non–small-cell lung cancer. U...

Clinical Pearls for Subcutaneous Delivery: Optimizing Anti-CD38 Use in Multiple Myeloma 03.06.2026 1:04:10

Please visit answersincme.com/860/2026-MC-001665-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ajai Chari, MD; Caitlin Costello, MD; and Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO. In this activity, experts in multiple myeloma (MM) discuss the therapeutic rationale, clinical data, and practical integration o...

Expanding the Use of HER2-Directed ADCs Into Early-Stage Breast Cancer: Multidisciplinary Conversations on (Neo)Adjuvant Care 20.05.2026 1:01:07

Please visit answersincme.com/860/101385133-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter A. Fasching, MD; Michael Gnant, MD, FACS; and Cristina Saura Manich, MD, PhD. In this activity, experts in breast cancer discuss new evidence in neoadjuvant and adjuvant care of early disease. Upon completion of this activity...

Personalized Treatment Strategies With First-Line Immunotherapy-Based Regimens in Advanced Colorectal Cancer and Biliary Tract Cancer 18.05.2026 23:53

Please visit answersincme.com/PNQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rachel Goodwin, MSc, MD, FRCPC; and Vincent Tam, MD. In this activity, experts in colorectal cancer and biliary tract cancer discuss first-line immunotherapy considerations. Upon completion of this activity, participants should be better able to...

KIT D816V in Focus: Optimizing Diagnosis and TKI Therapy in Advanced Systemic Mastocytosis 15.05.2026 14:03

Please visit answersincme.com/CKX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prithviraj Bose, MD. In this activity, an expert in hematology discusses the role of current and emerging treatment options for patients living with advanced systemic mastocytosis. Upon completion of this activity, participants should be better...

Cracking the Code of KRAS-Mutant NSCLC: Evidence for Emerging Therapies in First-Line Settings 13.05.2026 14:28

Please visit answersincme.com/GYB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Pasi A. Jänne, MD, PhD, FASCO. In this activity, an expert in oncology discusses the role of emerging KRAS inhibitors in the treatment paradigm for non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be bett...

Sebastien J. Hotte, MD, FRCPC - An Integrated Approach to Optimizing Radioligand Therapy and Bone Health Management in mCRPC 12.05.2026 16:59

Please visit answersincme.com/NZU860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sebastien J. Hotte, MD, FRCPC. In this activity, an expert in oncology discusses radioligand therapy for metastatic castration-resistant prostate cancer. Upon completion of this activity, participants should be better able to: Evaluate how the c...

30-Minute Power Briefing: ICIs in Frontline Advanced Classical Hodgkin Lymphoma—What’s New and What’s Now? 08.05.2026 36:24

Please visit answersincme.com/860/102771731-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sairah Ahmed, MD; and Sharon Marie Castellino, MD, MSc. In this activity, experts in Hodgkin lymphoma discuss unmet needs and emerging data in the treatment of classical HL. Upon completion of this activity, participants should be...

From Burden to Breakthrough: The Rise of KIT D816V-Selective Therapy in Indolent Systemic Mastocytosis 05.05.2026 14:12

Please visit answersincme.com/ZTY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Daniel J. DeAngelo, MD, PhD. In this activity, an expert in hematology discusses targeted treatment options for the management of indolent systemic mastocytosis. Upon completion of this activity, participants should be better able to: Recognize...

Guidance on Menopause-Related Vasomotor Symptom Management: A Focus on Neurokinin-Targeted Treatment Options 30.04.2026 26:38

Please visit answersincme.com/NYR860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jill Liss, MD, MSCP; Denise Black, MD, FRCSC; and Danielle Covarrubias. In this activity, experts in women’s health, joined by a patient advocate, discuss the burden of menopause-related vasomotor symptoms (VMS) and novel management strategies....

From Evidence to Practice: Where Do BCMA Bispecific Antibodies and Anti-CD38 mAb Combinations Fit Into Community Care for RRMM? 27.04.2026 1:03:36

Please visit answersincme.com/860/102653681-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jesus Berdeja, MD; and Saad Z. Usmani, MD, MBA, FACP, FASCO. In this activity, experts in multiple myeloma (MM) discuss how BCMA bispecific antibody (BsAb)–anti-CD38 monoclonal antibody combinations fit into the treatment paradigm...

Evolving Care in B-ALL: From Questions to Answers on the Role of CD19 Bispecific T-Cell Engagers 24.04.2026 19:58

Please visit answersincme.com/AXB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Bijal Shah, MD, MS. In this activity, an expert in oncology discusses B-cell acute lymphoblastic leukemia. Upon completion of this activity, participants should be better able to: Describe the rationale for the development of novel dual CD19 x C...

Navigating Urologic Cancer Care Across the Map: Getting up to Speed on the Latest Systemic Therapies for Renal Cell Carcinoma and Advanced Urothelial Carcinoma 23.04.2026 1:10:26

Please visit answersincme.com/860/240201307-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aly-Khan A. Lalani, MD, FRCPC; Normand Blais, MD, MSc; and Dorothy Lo, MD, FRCP(C), MHSc, PhD. In this activity, experts in managing urothelial carcinoma and renal cell carcinoma (RCC) from across Canada discuss evidence-based str...

Management of High-Risk CLL in the BTK Inhibitor Era: Frontline to Double-Refractory Disease 20.04.2026 1:01:53

Please visit answersincme.com/860/240201373-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Julie Stakiw, MD, FRCPC; and Constantine S. Tam, MBBS, MD. In this activity, experts in chronic lymphocytic leukemia (CLL) use case examples to discuss treatment management of high-risk CLL in both the frontline and relapsed/refrac...

Navigating Urologic Cancer Care Across the Map: Getting up to Speed on the Latest Systemic Therapies for Renal Cell Carcinoma and Advanced Urothelial Carcinoma 17.04.2026 1:11:22

Please visit answersincme.com/860/240201307-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aly-Khan A. Lalani, MD, FRCPC; Normand Blais, MD, MSc; Krista Noonan, BSc, MD, FRCPC and Eleftherios Soleas, PhD In this activity, experts in managing urothelial carcinoma and renal cell carcinoma (RCC) from across Canada discuss...

The ON Switch: Overcoming KRAS Resistance Using Next-Generation Targeted Inhibitors in Advanced NSCLC 15.04.2026 12:35

Please visit answersincme.com/AZB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Salman R. Punekar, MD, MSc. In this activity, an expert in the management of non–small-cell lung cancer (NSCLC) discusses the unmet treatment needs with current RAS(OFF) inhibitors and the potential role for emerging next-generation RAS(ON) inhi...

The Next Wave of CAR T Innovation for RRMM: Insights Into Emerging GPRC5D-Directed CAR T-Cell Therapies 10.04.2026 15:21

Please visit answersincme.com/KTB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Krina Patel, MD, MSc. In this activity, Krina Patel, MD, MSc, an expert in multiple myeloma, discusses emerging GPRC5D CAR T-cell therapies in relapse/refractory multiple myeloma. Upon completion of this activity, participants should be better a...

Navigating Urologic Cancer Care Across the Map: Getting up to Speed on the Latest Systemic Therapies for Renal Cell Carcinoma and Advanced Urothelial Carcinoma 10.04.2026 1:10:06

Please visit answersincme.com/860/240201307-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Normand Blais, MD, MSc; Aly-Khan A. Lalani, MD, FRCPC; Wassim Kassouf, MD; and Eleftherios Soleas, PhD. In this activity, experts in managing urothelial carcinoma and renal cell carcinoma (RCC) from across Canada discuss evidence-...